P‐glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF‐β signaling pathway inhibitor galunisertib-Reference-Cited by-同舟云学术

P‐glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF‐β signaling pathway inhibitor galunisertib

Published:2019-07-27 Issue:6 Volume:146 Page:1631-1642
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Li Wenlong¹,Tibben Matthijs²,Wang Yaogeng¹,Lebre Maria C.¹,Rosing Hilde²,Beijnen Jos H.¹²³,Schinkel Alfred H.¹^ORCID

Affiliation:

1. The Netherlands Cancer InstituteDivision of Pharmacology Amsterdam The Netherlands

2. The Netherlands Cancer InstituteDepartment of Pharmacy & Pharmacology Amsterdam The Netherlands

3. Utrecht UniversityFaculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology Utrecht The Netherlands

Funder

China Scholarship Council

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32568

Reference35 articles.

1. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues.

2. Specificity, diversity, and regulation in TGF‐β superfamily signaling

3. TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders

4. The transforming growth factor-β system, a complex pattern of cross-reactive ligands and receptors

5. Hallmarks of Cancer: The Next Generation

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictability of human exposure by human‐CYP3A4‐transgenic mouse models: A meta‐analysis;Clinical and Translational Science;2023-12

2. The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs;Biomedicine & Pharmacotherapy;2022-05

3. Assessing cytochrome P450 function using genetically engineered mouse models;Pharmacology and Toxicology of Cytochrome P450 – 60th Anniversary;2022

4. ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib;Pharmacological Research;2021-10

5. ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib;Molecular Cancer Therapeutics;2021-03-30